NCT06768905 2026-04-16
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
Clinical Trials
33 trialsNCT06218602 2026-04-15
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07052305 2026-04-09
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Washington University School of Medicine
Phase 1 Recruiting
NCT05852717 2026-04-08
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06104592 2026-03-31
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07489989 2026-03-24
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
Chinese PLA General Hospital
Phase 2 Recruiting
NCT06784726 2026-03-13
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
Phase 2 Recruiting
NCT06481228 2026-03-02
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT06481241 2026-03-02
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT05991388 2026-02-20
Glo-BNHL
University of Birmingham
Phase 2/3 Recruiting
NCT04512716 2026-02-17
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05800405 2026-02-04
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
City of Hope Medical Center
Phase EARLY_PHASE1 Recruiting
NCT06834373 2026-01-28
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Mayo Clinic
Phase 2 Recruiting
NCT04545762 2026-01-14
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
Phase 1 Recruiting
NCT05260957 2025-12-31
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
University of Miami
Phase 2 Recruiting
NCT07280494 2025-12-12
S101MRD
Peking University People's Hospital
Phase 1 Recruiting
NCT07053670 2025-11-17
CT1190B
Tongji Hospital
Phase 1 Recruiting
NCT06854159 2025-09-29
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
University of California, Davis
Phase 2 Recruiting
NCT07097207 2025-07-31
CAR-T
Shenzhen University General Hospital
Phase 1/2 Recruiting
NCT02917083 2025-07-25
RELY-30
Baylor College of Medicine
Phase 1 Recruiting
NCT06815029 2025-06-26
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
City of Hope Medical Center
Phase 1 Recruiting
NCT06822868 2025-02-12
CT1190B
Beijing GoBroad Hospital
Phase 1 Recruiting
NCT06796517 2025-01-28
Immunotherapy in Lymphoma
Seoul St. Mary's Hospital
Recruiting
NCT06734871 2025-01-03
CT1190B
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase 1 Recruiting
NCT06752785 2024-12-31
CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
Guangzhou Women and Children's Medical Center
Phase 1 Recruiting
NCT06698484 2024-11-21
CAR-T for NHL
National University of Malaysia
Phase 2 Recruiting
NCT06439173 2024-06-03
Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment
Instituto de Investigación Biomédica de Salamanca
Recruiting
NCT05052528 2024-05-13
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
University of California, Davis
Phase 1 Recruiting
NCT06381830 2024-04-24
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT06355739 2024-04-09
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT05043571 2021-09-14
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
National University Hospital, Singapore
Phase 1 Recruiting
NCT05038696 2021-09-09
ALaCART
National University Hospital, Singapore
Phase 1 Recruiting
NCT04532203 2020-10-26
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies
Zhejiang University
Phase EARLY_PHASE1 Recruiting